Pyrilutamide

Pyrilutamide

Clinical data
Other names	Pyrilutamide; KX-826
Routes of administration	Topical
Drug class	Nonsteroidal antiandrogen
ATC code	None
Identifiers
IUPAC name 4-(3-(4-cyano-2-fluoro-3-(trifluoromethyl)2-tolyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide
Chemical and physical data
Formula	C21H16F5N4O2S
Molar mass	483.44 g·mol−1
3D model (JSmol)	Interactive image
SMILES CNC(=O)C1=C(F)C=C(C=C1)N1C(=S)N(C(=O)C1(C)C)C1=C(F)C(=C(C=C1)C#N)C(F)(F)F

Pyrilutamide(developmental code name KX-826) is is a nonsteroidal antiandrogen (NSAA) – specifically, a selective high-affinity silent antagonist of the androgen receptor (AR) – which is under development by Suzhou Kintor Pharmaceuticals, inc., a subsidiary of Kintor Pharmaceutical Limited, for the potential treatment of Androgentic Alopecia in males and females in China and the United States of America.

= Androgenetic Alopecia

Pyrilutamide has successfully completed phase II clinical trials in China and is currently in phase II clinical trials in the U.S for the potential treatment of Androgenetic Alopecia in males. It is currently in phase II clinical trials in China for the potential treatment of Androgenetic Alopecia in females. The drug is about to enter phase III clinical trials in China which will be conducted over 24 weeks across more than 20 sites in China with a sample size of 416. The primary endpoint is the change from baseline in non-vellus target area hair count (TAHC) at the end of week 24. The drug will be dosed at 5mg (0.5%) per patient per day in the trial which is expected to start in Q1 2022.

References

Suzhou Kintor Pharmacueticals, Inc. Substituted Thioimidazolidinone androgen receptor antagonists and uses thereof. C.A. Patent No.2829322